205 related articles for article (PubMed ID: 17329510)
1. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk.
Lurie G; Thompson P; McDuffie KE; Carney ME; Terada KY; Goodman MT
Obstet Gynecol; 2007 Mar; 109(3):597-607. PubMed ID: 17329510
[TBL] [Abstract][Full Text] [Related]
2. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.
Maxwell GL; Schildkraut JM; Calingaert B; Risinger JI; Dainty L; Marchbanks PA; Berchuck A; Barrett JC; Rodriguez GC
Gynecol Oncol; 2006 Nov; 103(2):535-40. PubMed ID: 16740300
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptives and epithelial ovarian cancer. Does dose matter?
Sanderson M; Williams MA; Weiss NS; Hendrix NW; Chauhan SP
J Reprod Med; 2000 Sep; 45(9):720-6. PubMed ID: 11027080
[TBL] [Abstract][Full Text] [Related]
4. Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer.
Faber MT; Jensen A; Frederiksen K; Glud E; Høgdall E; Høgdall C; Blaakaer J; Kjaer SK
Cancer Causes Control; 2013 Dec; 24(12):2197-206. PubMed ID: 24077761
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.
Sidney S; Petitti DB; Soff GA; Cundiff DL; Tolan KK; Quesenberry CP
Contraception; 2004 Jul; 70(1):3-10. PubMed ID: 15208046
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptive tolerance: does the type of pill matter?
Moreau C; Trussell J; Gilbert F; Bajos N; Bouyer J
Obstet Gynecol; 2007 Jun; 109(6):1277-85. PubMed ID: 17540798
[TBL] [Abstract][Full Text] [Related]
7. Epithelial ovarian cancer and combined oral contraceptives. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Int J Epidemiol; 1989 Sep; 18(3):538-45. PubMed ID: 2807655
[TBL] [Abstract][Full Text] [Related]
8. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer.
Greer JB; Modugno F; Allen GO; Ness RB
Obstet Gynecol; 2005 Apr; 105(4):731-40. PubMed ID: 15802398
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study.
Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Persson IR
Gynecol Oncol; 2001 Dec; 83(3):575-85. PubMed ID: 11733975
[TBL] [Abstract][Full Text] [Related]
10. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis.
Modugno F; Ness RB; Allen GO; Schildkraut JM; Davis FG; Goodman MT
Am J Obstet Gynecol; 2004 Sep; 191(3):733-40. PubMed ID: 15467532
[TBL] [Abstract][Full Text] [Related]
11. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.
Glud E; Kjaer SK; Thomsen BL; Høgdall C; Christensen L; Høgdall E; Bock JE; Blaakaer J
Arch Intern Med; 2004 Nov; 164(20):2253-9. PubMed ID: 15534163
[TBL] [Abstract][Full Text] [Related]
12. Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects.
Lurie G; Wilkens LR; Thompson PJ; McDuffie KE; Carney ME; Terada KY; Goodman MT
Epidemiology; 2008 Mar; 19(2):237-43. PubMed ID: 18223481
[TBL] [Abstract][Full Text] [Related]
13. Low-dose oral contraceptives: progestin potency, androgenicity, and atherogenic potential.
Ellis J
Clin Ther; 1986; 8(6):607-18. PubMed ID: 3539347
[TBL] [Abstract][Full Text] [Related]
14. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk.
Schildkraut JM; Calingaert B; Marchbanks PA; Moorman PG; Rodriguez GC
J Natl Cancer Inst; 2002 Jan; 94(1):32-8. PubMed ID: 11773280
[TBL] [Abstract][Full Text] [Related]
15. Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database.
Murphy PA; Brixner D
Contraception; 2008 Apr; 77(4):257-63. PubMed ID: 18342648
[TBL] [Abstract][Full Text] [Related]
16. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer.
Strom BL; Berlin JA; Weber AL; Norman SA; Bernstein L; Burkman RT; Daling JR; Deapen D; Folger SG; Malone KE; Marchbanks PA; Simon MS; Ursin G; Weiss LK; Spirtas R
Contraception; 2004 May; 69(5):353-60. PubMed ID: 15105056
[TBL] [Abstract][Full Text] [Related]
17. [Cardiovascular risks of oral contraceptives: dose-response relationship].
Kelleher CC
Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
[TBL] [Abstract][Full Text] [Related]
18. Menopausal hormones and risk of ovarian cancer.
Moorman PG; Schildkraut JM; Calingaert B; Halabi S; Berchuck A
Am J Obstet Gynecol; 2005 Jul; 193(1):76-82. PubMed ID: 16021062
[TBL] [Abstract][Full Text] [Related]
19. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
20. Hormone replacement therapy and risk of epithelial ovarian cancer.
Purdie DM; Bain CJ; Siskind V; Russell P; Hacker NF; Ward BG; Quinn MA; Green AC
Br J Cancer; 1999 Oct; 81(3):559-63. PubMed ID: 10507786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
